Teva Pharmaceutical Industries ADR (TEVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 369,000 | 1,418,000 | 937,000 | 503,000 | 220,000 |
| Depreciation Amortization | 239,000 | 1,002,000 | 742,000 | 494,000 | 244,000 |
| Income taxes - deferred | -22,000 | -671,000 | -76,000 | -183,000 | 28,000 |
| Accounts receivable | N/A | -173,000 | N/A | N/A | N/A |
| Other Working Capital | -617,000 | -1,366,000 | -1,595,000 | -1,035,000 | -700,000 |
| Other Operating Activity | -9,000 | 1,439,000 | 483,000 | 343,000 | 103,000 |
| Operating Cash Flow | $-40,000 | $1,649,000 | $491,000 | $122,000 | $-105,000 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -126,000 | -467,000 | -325,000 | -197,000 | -110,000 |
| Purchase Of Investment | N/A | -57,000 | -40,000 | -27,000 | -11,000 |
| Sale Of Investment | N/A | 42,000 | N/A | N/A | N/A |
| Other Investing Activity | 355,000 | 1,219,000 | 937,000 | 661,000 | 322,000 |
| Investing Cash Flow | $229,000 | $737,000 | $572,000 | $437,000 | $201,000 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 2,298,000 | 2,298,000 | 2,305,000 | N/A |
| Debt Repayment | -23,000 | -4,112,000 | -4,112,000 | -3,668,000 | -1,368,000 |
| Common Stock Repurchased | N/A | -38,000 | N/A | N/A | N/A |
| Dividend Paid | N/A | -340,000 | -340,000 | -340,000 | -340,000 |
| Other Financing Activity | 36,000 | 41,000 | -37,000 | -35,000 | -36,000 |
| Financing Cash Flow | $13,000 | $-2,151,000 | $-2,191,000 | $-1,738,000 | $-1,744,000 |
| Exchange Rate Effect | -17,000 | 21,000 | 31,000 | 40,000 | 45,000 |
| Beginning Cash Position | 3,556,000 | 3,300,000 | 3,300,000 | 3,300,000 | 3,300,000 |
| End Cash Position | 3,741,000 | 3,556,000 | 2,203,000 | 2,161,000 | 1,697,000 |
| Net Cash Flow | $185,000 | $256,000 | $-1,097,000 | $-1,139,000 | $-1,603,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | -40,000 | 1,649,000 | 491,000 | 122,000 | -105,000 |
| Capital Expenditure | -168,000 | -501,000 | -359,000 | -223,000 | -127,000 |
| Free Cash Flow | -208,000 | 1,148,000 | 132,000 | -101,000 | -232,000 |